Stocks and Sips

Stocks and Sips - Xenitra Ltd (ASX:XEN)

Our Stocks and Sips evening with Xenitra (ASX:XEN) featured a live Q&A with Dr Anthony Noble, Non-Executive Chairman, who shared insights into Xenitra's integrated digital commerce platform connecting global brands with Chinese consumers. The discussion explored XEN's three growth pillars - nutraceuticals, OTC pharmaceuticals, and real-world-asset tokenisation - alongside the company's brand partnership strategy, approach to regulatory risk, and outlook for long-term growth, followed by drinks, gourmet food, and networking at the Sharewise office.

Date
May 7, 2026
Time
6:00 - 8:30 PM AEST
Venue
Sharewise Office, Milsons Point
Entry
Free
Stocks and Sips - Xenitra Ltd (ASX:XEN)Stocks and Sips - Xenitra Ltd (ASX:XEN)

Event recap

At our latest Stocks and Sips event, we welcomed Dr Anthony Noble, Non-Executive Chairman of Xenitra Limited (ASX:XEN), for an in-depth discussion hosted by Sharewise CEO Alex Perry.

Xenitra is one of the few ASX-listed vehicles offering direct exposure to China's fast-growing consumer and healthcare markets. Through its channel-optimised sales platform - spanning B2B trading, retail distribution, and all major Chinese e-commerce platforms - XEN has generated over $70m in sales since 2024 and secured a $30m offtake agreement for global brands. The recent acquisition of Fukang OTC Pharmacy and the launch of the OPAL token and Xen Shop position the company at the intersection of cross-border FMCG, consumer healthcare, and Web3-enabled retail.

Anthony shared insights on:

  • Xenitra's journey since his appointment as Chairman in March 2025, and what he believes the market may be underappreciating today
  • Where Xenitra is most differentiated in how it connects global brands with Chinese consumers, and the key drivers behind its recent revenue growth and offtake agreement
  • The long-term opportunities across XEN's three core categories - nutraceuticals, OTC pharmaceuticals, and tokenisation - and the brand partnership pipeline supporting its next phase of growth
  • How real-world asset tokenisation works in practice through the OPAL token and Xen Shop, the customer experience it enables, and early commercial outcomes compared with traditional e-commerce models
  • Xenitra's approach to regulatory risk amid China's evolving stance on digital assets and cross-border e-commerce, and the flexibility built into the model to adapt to changes in the operating environment
  • The role of the Nutritionals business going forward, following streamlining, cost reductions, and the implementation of a leaner management structure
  • How investors should think about closing the gap between Xenitra's commercial delivery and broader market sentiment on China-exposed names
  • The key factors Anthony believes will ultimately determine Xenitra's long-term success

The evening brought together Sharewise clients for thoughtful discussion, live Q&A, and networking over drinks and gourmet food at the Sharewise office in Milsons Point.

About the event

Join Sharewise on Thursday 7 May 2026 for an exclusive Stocks and Sips evening with Dr Anthony Noble, Non-Executive Chairman of Xenitra Limited (ASX:XEN), for a live Q&A exploring how XEN is building an integrated digital commerce ecosystem for Asian markets.

XEN is one of the few ASX-listed vehicles offering direct exposure to China's fast-growing consumer and healthcare markets. Through its channel-optimised sales platform - spanning B2B trading, retail distribution, and all major Chinese e-commerce platforms - XEN has generated over $70m in sales since 2024, with Q3 revenue of $8.3m, up more than 300% QoQ, and a $30m offtake agreement for global brands validating its execution capability. The recent acquisition of Fukang OTC Pharmacy, combined with its Hong Kong pharmaceutical licence, positions XEN to capture what management believes is a structural inflection point in China's OTC market - comparable to the infant formula boom a decade ago. Meanwhile, the launch of the OPAL token and Xen Shop places XEN at the forefront of Web3-enabled retail, with blockchain tied directly to real-world consumer goods.

After the discussion, guests are invited to stay for drinks, gourmet food, and networking in a relaxed setting at the Sharewise office in Milsons Point, with complimentary merch to take home.

Limited spaces available - reserve yours to secure your seat at this exclusive event.

Discussion topics

Real World Asset tokenisation - what it is, how it works in China, and the commercial outcomes of the OPAL token and Xen Shop

The OTC medicine opportunity in China via cross-border e-commerce, and how the Fukang Pharmacy acquisition and Hong Kong pharmaceutical licence accelerate this business unit

Current and target brand partnerships across nutraceuticals, OTC, and tokenised commerce channels

The new board, lean management structure, and the streamlining, cost reductions, and simplification of the Nutritionals business

Live audience Q&A

Agenda

6:00 PM Arrival

6:30 PM Q&A with Dr Anthony Noble

7:00 PM Networking over drinks & gourmet food

8:30 PM Event concludes

Featured companies

Xenitra Ltd (ASX:XEN)

Cross-border consumer and healthcare

Xenitra specialises in fast-moving consumer goods (FMCG), nutraceuticals, over-the-counter (OTC) medicine and personal care products that are sold through a channel optimised sales ecosystem including blockchain tokenised distribution channels spanning Business-to-Business (B2B) trading, retail distribution and all major ecommerce platforms in China. Xenitra works with leading international brands as a market entry and sales acceleration partner for Asian markets. Through our proprietary platform, we have a proven track record of delivering exceptional market integration, providing marketing insights and delivering sales velocity for brands in China.

Speakers

Dr Anthony Noble
Dr Anthony Noble
Non-Executive Chairman, Xenitra Ltd (ASX:XEN)
Read bio

Anthony was appointed Non-Executive Chairman in March 2025. He has more than 20 years’ experience working across life sciences, consumer health, and international trade, with a focus on building partnerships and creating sustainable growth. Anthony holds a PhD in Stem Cell Biology and an Executive MBA from the Australian Graduate School of Management, including a year at the Wharton School (UPenn). His career has spanned from biotechnology research and clinical development to operational and commercial leadership roles in both listed and private companies. He currently serves as Executive Director at Servatus Biopharmaceuticals and Biomiq Skincare. He previously was CEO of The Calmer Co. Ltd and Australian Biotherapeutics. Anthony spent a decade in various roles within the SFI Health Group where he was Global Head of Innovation and spearheaded market expansion initiatives via both organic growth and multiple M&A transactions in Europe, Australia, North America and in Asia, with a strong focus on the North Asia markets, including serving as General Manager of both SFI-Shineway in China and of SFI-Korea. His focus at Xenitra has been on strengthening the company’s compliance and governance practices, tightening and defining the strategic direction, supporting senior management in China, and ensuring the business is well-positioned to take advantage of growing opportunities in cross-border trade.

Read bio
Read bio

Register to attend

Attendance is free and spots are limited. Register to receive your QR code for check-in on the night.

Is it free to attend?

Yes - free (limited spots available). Registration is essential.

Where is the event held?

Sharewise, Level 9, 68 Alfred St S, Milsons Point.

What food and drinks are included?

Drinks: Open bar. Food: Gourmet food served during networking.

What is the dress code?

Business casual.

Is there an age limit?

Yes - this is an 18+ event.

Stocks and Sips - Xenitra Ltd (ASX:XEN)
✓ 100% free report
✓ Instant delivery
✓ No card required
✓ Compiled by our analysts

More events

All events →

You've met the management. Now meet our Advisors

The team behind Stocks and Sips works with clients every day on research, advisory and execution across ASX, US and global markets.

Explore our services →